Autopsy report · NCT06056310
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Cause of deathOther
“No major safety concerns were identified in HyperlynX study, but Lack of evidence of efficacy of meaningful clinical benefit.”
Life of this trial
- Registered 4 months before it started.
- Ran for about 7 months before it stopped.
- 18 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Sponsor type
- Industry
- Conditions
- Head and Neck Cancer
- Interventions
- Xevinapant; Cisplatin; intensity-modulated radiation therapy (IMRT)
- Participants
- 18
- Sites
- 23
- Countries
- Belgium, Israel, South Korea, Spain, Taiwan, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.